Search Results 1031-1040 of 3698 for Solid
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is required except for subjects with bone only disease. All prior ...
... Solid Tumors (RECIST) 1.1 as determined by the central imaging vendor; Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Has a ...
... Solid Tumors, Version 1.1 (RECIST v1.1); Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; Adequate hematologic, renal and hepatic ...
Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of ...
Subject with a current malignancy including solid tumors and hematologic malignancies whose thrombocytopenia may be attributed to chemotherapy. Hepatic ...
Unleashing CAR-T cell therapy to destroy solid tumors in thyroid cancer · Teamwork and a new nickname inspire patient through pancreatic cancer treatment · Mayo ...
Prior solid organ transplantation. Prior therapy with any known inhibitor of MNK1 orMNK2. Ongoing immunosuppressive therapy, including systemic or enteric ...
... Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating ...
... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.